MGNX

MacroGenics is a clinical-stage biopharma whose $150M of FY2025 revenue is not product commerce but the residue of past deals — royalties/economics on out-licensed or sold assets (ZYNYZ, MARGENZA, TZIELD) plus contract-manufacturing to offset facility costs. Revenue was flat YoY (-0.3%) and has been erratic ($77M→$152M→$59M→$150M→$150M), so there is no durable top-line to underwrite. Beneath it the business loses money structurally: -48.7% operating margin, -49.9% net margin, a -$74.6M net loss that widened 11.4%, and -$81M of operating cash flow. R&D of $147M essentially equals total revenue — this is a research shop funded by external capital, not a self-sustaining company.

The balance sheet is the disqualifier. Cash fell 68.7% to $57.2M while total liabilities jumped 38.2% and stockholders' equity was cut in half to $55.6M, leaving liabilities at 3.62x equity against a -$1.24B accumulated deficit. Management itself frames the picture: cash, equivalents and marketable securities 'combined with projected and anticipated future payments from our partners, and anticipated savings from our cost-reduction initiatives, will support our cash runway into late 2027.' Against ~$81M annual burn, that is a hard financing wall roughly 18 months out — and for a sub-$300M-cap name reliant on equity markets, the near-certain resolution is dilution of the 63.6M share base. Near-term liquidity looks superficially fine (current assets $220M vs $43.1M current liabilities), but that cushion is being consumed, not compounded.